{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:20:15Z","timestamp":1770524415809,"version":"3.49.0"},"reference-count":64,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Chemotherapy-induced peripheral neuropathy (CIPN) from oxaliplatin and taxane drugs is a bothersome toxicity. Palmitoylethanolamide (PEA) has been reported to improve myelinated nerve fiber function in patients experiencing painful CIPN. We conducted a double-blind, placebo-controlled, randomized trial of PEA in patients with established CIPN. Methods: Eligible patients were adults who had pain, numbness, tingling, or other symptoms of CIPN for at least three months following completion of paclitaxel, oxaliplatin, or cisplatin-based chemotherapy. Study patients were randomized to one of the two treatment groups (PEA versus placebo, both administered either once or twice daily). The CIPN20 questionnaire was assessed weekly. Results: A total of 17 males and 71 females participated in the study; most had neuropathy from paclitaxel. Most (85%) finished 8 weeks of treatment. There was no suggestion that either of the PEA arms did any better than the combined placebo arms. There was no signal of significant toxicity differences between the three study arms. Quality of life outcome measures were similar between the study arms, as were cognitive function evaluations. Discussion: PEA failed to improve established CIPN. Future trials might explore whether PEA may be effective in preventing CIPN or cognitive changes based on data that suggest it may be helpful in this situation. Conclusions: PEA failed to improve established chemotherapy-induced neuropathy.<\/jats:p>","DOI":"10.3390\/cancers16244244","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T04:07:40Z","timestamp":1734667660000},"page":"4244","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study"],"prefix":"10.3390","volume":"16","author":[{"given":"Mellar P.","family":"Davis","sequence":"first","affiliation":[{"name":"Levine Cancer Center, Charlotte, NC 28204, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1256-485X","authenticated-orcid":false,"given":"Angela","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Biostatistics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Segal","sequence":"additional","affiliation":[{"name":"Cone Health Cancer Center, Greensboro, NC 27403, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Gudena","sequence":"additional","affiliation":[{"name":"Cone Health Cancer Center, Greensboro, NC 27403, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy","family":"D\u2019Andre","sequence":"additional","affiliation":[{"name":"Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4640-9197","authenticated-orcid":false,"given":"Karthik V.","family":"Giridhar","sequence":"additional","affiliation":[{"name":"Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsi K.","family":"Vasireddy","sequence":"additional","affiliation":[{"name":"Carle Clinic, Urbana, IL 61801, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3146-7231","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel-Ghani","family":"Azzouqa","sequence":"additional","affiliation":[{"name":"Monument Health, Rapid City, SD 57701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Novotny","sequence":"additional","affiliation":[{"name":"Biostatistics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaylene","family":"McCue","sequence":"additional","affiliation":[{"name":"Biostatistics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3453-6906","authenticated-orcid":false,"given":"Brent","family":"Bauer","sequence":"additional","affiliation":[{"name":"Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5752","authenticated-orcid":false,"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhang, J., Xu, H.X., Wu, Y.L., Cho, W.C.S., Xian, Y.F., and Lin, Z.X. (2023). Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling. Adv. Biol., 7.","DOI":"10.1002\/adbi.202300062"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40487-023-00233-8","article-title":"Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam","volume":"11","author":"Le","year":"2023","journal-title":"Oncol. Ther."},{"key":"ref_3","first-page":"30","article-title":"Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel\/Nab-Paclitaxel","volume":"102","author":"Imai","year":"2023","journal-title":"Oncology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.resinv.2023.06.002","article-title":"Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study","volume":"61","author":"Omori","year":"2023","journal-title":"Respir. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.22.02766","article-title":"Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study","volume":"41","author":"Ozols","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clcc.2023.08.003","article-title":"Trends and Prescriber Variation in the Duration of Oxaliplatin-Containing Adjuvant Chemotherapy for Stage III Colon Cancer From 2007 to 2019: A Population-Based Retrospective Cohort Study","volume":"22","author":"Sutradhar","year":"2023","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajco.13965","article-title":"Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter?","volume":"20","author":"Yoon","year":"2023","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"151499","DOI":"10.1016\/j.soncn.2023.151499","article-title":"Real-Life Experiences of Chemotherapy-Induced Peripheral Neuropathy in Patients with Cancer: A Qualitative Meta-Synthesis Study","volume":"39","author":"Kim","year":"2023","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/164_2022_609","article-title":"Chemotherapy-Induced Peripheral Neuropathy","volume":"277","author":"Chen","year":"2023","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_10","first-page":"1030","article-title":"Chemotherapy-Induced Peripheral Neuropathy: A Challenge for Clinicians","volume":"30","author":"Abdi","year":"2016","journal-title":"Oncology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ALN.0000000000001085","article-title":"Is Chemotherapy-induced Peripheral Neuropathy More Than Just a Peripheral Nervous System Disorder?","volume":"124","author":"Dougherty","year":"2016","journal-title":"Anesthesiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00520-011-1141-9","article-title":"The relationship between numbness, tingling, and shooting\/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA","volume":"20","author":"Wolf","year":"2012","journal-title":"Support. Care Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp-2017-317215","article-title":"Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort","volume":"89","author":"Shah","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-16366-6_6","article-title":"Symptoms: Chemotherapy-Induced Peripheral Neuropathy","volume":"862","author":"Schneider","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00520-023-07850-z","article-title":"The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients","volume":"31","author":"Hines","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1111\/ajco.13804","article-title":"Taxane-induced neuropathy: How serious is this problem for patients with early breast cancer?","volume":"19","author":"Nicolae","year":"2023","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/ajco.13923","article-title":"Risk factors for taxane-induced peripheral neuropathy in patients with breast cancer","volume":"20","author":"Liang","year":"2023","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/19390211.2021.2005733","article-title":"Palmitoylethanolamide: A Potential Alternative to Cannabidiol","volume":"20","author":"Clayton","year":"2023","journal-title":"J. Diet. Suppl."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Murru, E., Muntoni, A.L., Manca, C., Aroni, S., Pistis, M., Banni, S., and Carta, G. (2022). Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARalpha Agonist Fenofibrate-Treated Mice. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010709"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"136648","DOI":"10.1016\/j.neulet.2022.136648","article-title":"Palmitoylethanolamide ameliorates neuroinflammation via modulating PPAR-alpha to promote the functional outcome after intracerebral hemorrhage","volume":"781","author":"Zhou","year":"2022","journal-title":"Neurosci. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bph.12029","article-title":"Activation and desensitization of TRPV1 channels in sensory neurons by the PPARalpha agonist palmitoylethanolamide","volume":"168","author":"Ambrosino","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/bjp.2008.324","article-title":"\u2019Entourage\u2019 effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors","volume":"155","author":"Ho","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tvjl.2005.10.003","article-title":"Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals","volume":"173","author":"Re","year":"2007","journal-title":"Vet. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.bjp.0704199","article-title":"Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide","volume":"133","author":"Jonsson","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hohmann, U., Pelzer, M., Kleine, J., Hohmann, T., Ghadban, C., and Dehghani, F. (2019). Opposite Effects of Neuroprotective Cannabinoids, Palmitoylethanolamide, and 2-Arachidonoylglycerol on Function and Morphology of Microglia. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.01180"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1097\/j.pain.0000000000000687","article-title":"N-palmitoylethanolamide in the anterior cingulate cortex attenuates inflammatory pain behaviour indirectly via a CB1 receptor-mediated mechanism","volume":"157","author":"Okine","year":"2016","journal-title":"Pain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/jpet.106.111385","article-title":"Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha","volume":"319","author":"LoVerme","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13041-015-0139-5","article-title":"Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice","volume":"8","author":"Guida","year":"2015","journal-title":"Mol. Brain"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Im, D.S. (2021). GPR119 and GPR55 as Receptors for Fatty Acid Ethanolamides, Oleoylethanolamide and Palmitoylethanolamide. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031034"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/can.2016.0030","article-title":"Palmitoylethanolamide Modulates GPR55 Receptor Signaling in the Ventral Hippocampus to Regulate Mesolimbic Dopamine Activity, Social Interaction, and Memory Processing","volume":"2","author":"Kramar","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/j.pain.0000000000003015","article-title":"Serum levels of endocannabinoids and related lipids in painful vs painless diabetic neuropathy: Results from the Pain in Neuropathy Study","volume":"165","author":"Backryd","year":"2023","journal-title":"Pain"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lang-Illievich, K., Klivinyi, C., Rumpold-Seitlinger, G., Dorn, C., and Bornemann-Cimenti, H. (2022). The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Nutrients, 14.","DOI":"10.3390\/nu14194084"},{"key":"ref_33","first-page":"328797","article-title":"Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: Pain relief and neuroprotection share a PPAR-alpha-mediated mechanism","volume":"2013","author":"Pacini","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Campolo, M., Lanza, M., Paterniti, I., Filippone, A., Ardizzone, A., Casili, G., Scuderi, S.A., Puglisi, C., Mare, M., and Memeo, L. (2021). PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF-kappaB\/Nrf-2 Axis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083927"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Di Cesare Mannelli, L., Pacini, A., Corti, F., Boccella, S., Luongo, L., Esposito, E., Cuzzocrea, S., Maione, S., Calignano, A., and Ghelardini, C. (2015). Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128080"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/jpet.116.236182","article-title":"Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice","volume":"359","author":"Donvito","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2174\/187152711799219307","article-title":"Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy","volume":"10","author":"Truini","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1159\/000519000","article-title":"Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO","volume":"44","author":"Zaiss","year":"2021","journal-title":"Oncol. Res. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mallard, A., Briskey, D., Richards, A., Mills, D., and Rao, A. (2020). The Effect of Orally Dosed Levagen+ (palmitoylethanolamide) on Exercise Recovery in Healthy Males-A Double-Blind, Randomized, Placebo-Controlled Study. Nutrients, 12.","DOI":"10.3390\/nu12030596"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/bph.13580","article-title":"The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations","volume":"174","author":"Petrosino","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Rankin, L., and Fowler, C.J. (2020). The Basal Pharmacology of Palmitoylethanolamide. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217942"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.irn.2017.08.004","article-title":"Impact of Inflammation on the Blood-Neural Barrier and Blood-Nerve Interface: From Review to Therapeutic Preview","volume":"137","author":"Skaper","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Petrosino, S., Cordaro, M., Verde, R., Schiano Moriello, A., Marcolongo, G., Schievano, C., Siracusa, R., Piscitelli, F., Peritore, A.F., and Crupi, R. (2018). Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00249"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/febs.12152","article-title":"Metabolism of endocannabinoids and related N-acylethanolamines: Canonical and alternative pathways","volume":"280","author":"Ueda","year":"2013","journal-title":"FEBS J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.13020","article-title":"Palmitoylethanolamide for the treatment of pain: Pharmacokinetics, safety and efficacy","volume":"82","author":"Gabrielsson","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-014-0136-0","article-title":"Micronized\/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain","volume":"11","author":"Impellizzeri","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1188\/17.ONF.580-588","article-title":"The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure","volume":"44","author":"Haupt","year":"2017","journal-title":"Oncol. Nurs. Forum"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1007\/s00520-017-3780-y","article-title":"Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel\/carboplatin-induced peripheral neuropathy in NCCTG\/Alliance clinical trials","volume":"25","author":"Kanwar","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2016.09.020","article-title":"Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population","volume":"69","author":"Mols","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1007\/s00520-019-04771-8","article-title":"Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy","volume":"27","author":"Yeo","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00520-018-4553-y","article-title":"Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data","volume":"27","author":"Smith","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ejp.1378","article-title":"Patients\u2019 Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice","volume":"23","author":"Perrot","year":"2019","journal-title":"Eur. J. Pain"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1097\/NCC.0b013e31820251de","article-title":"Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool","volume":"34","author":"Tofthagen","year":"2011","journal-title":"Cancer Nurs."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Little, R.J., and Rubin, D.B. (2019). Statistical Analysis with Missing Data, John Wiley & Sons.","DOI":"10.1002\/9781119482260"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Fairclough, D.L. (2010). Design and Analysis of Quality of Life Studies in Clinical Trials, CRC Press.","DOI":"10.1201\/9781420061185"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1212\/WNL.44.3_Part_1.488","article-title":"The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro","volume":"44","author":"Windebank","year":"1994","journal-title":"Neurology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1172\/JCI1130","article-title":"Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle","volume":"101","author":"Gill","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1871527311312010010","article-title":"Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries","volume":"12","author":"Esposito","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1742-2094-10-20","article-title":"Molecular evidence for the involvement of PPAR-delta and PPAR-gamma in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma","volume":"10","author":"Paterniti","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Elfarnawany, A., and Dehghani, F. (2022). Palmitoylethanolamide Mitigates Paclitaxel Toxicity in Primary Dorsal Root Ganglion Neurons. Biomolecules, 12.","DOI":"10.3390\/biom12121873"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Cristiano, C., Avagliano, C., Cuozzo, M., Liguori, F.M., Calignano, A., and Russo, R. (2022). The Beneficial Effects of Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain and Associated Mood Disorders Induced by Paclitaxel in Mice. Biomolecules, 12.","DOI":"10.3390\/biom12081155"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kim, N., Parolin, B., Renshaw, D., Deb, S.K., and Zariwala, M.G. (2024). Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over Trial. Nutrients, 16.","DOI":"10.3390\/nu16040489"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4244\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:56:12Z","timestamp":1760115372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":64,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16244244"],"URL":"https:\/\/doi.org\/10.3390\/cancers16244244","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}